Fig. 2.
Fig. 2. DLI-mediated GVL effects in mixed and full donor chimeras. / Cumulative data from 4 similar experiments are presented. DLI were administered on day 56 after BMT followed by intravenous injection of 500 EL4 cells on day 63 (↓). (A) Full chimeras receiving DLI and EL4 cells (▪, n = 20) showed a slight, but statistically significant, prolongation of survival compared to full chimeras receiving tumor cells only (■, n = 12; P < .001). Full chimeras receiving (▾, n = 14) or not receiving DLI (▿, n = 7) showed no treatment-related mortality. (B) Mixed chimeras receiving (♦, n = 11) or not receiving (⋄, n = 8) DLI showed no treatment-related mortality. Mixed chimeras receiving DLI and EL4 cells (●, n = 25) had significantly improved survival compared with mixed chimeras receiving EL4 alone (○, n = 14; P < .0001). (C) Mixed chimeras receiving DLI and EL4 cells (●, n = 25) had significantly improved survival compared with full chimeras receiving EL4 + DLI (▪, n = 20; P < .0001).

DLI-mediated GVL effects in mixed and full donor chimeras.

Cumulative data from 4 similar experiments are presented. DLI were administered on day 56 after BMT followed by intravenous injection of 500 EL4 cells on day 63 (↓). (A) Full chimeras receiving DLI and EL4 cells (▪, n = 20) showed a slight, but statistically significant, prolongation of survival compared to full chimeras receiving tumor cells only (■, n = 12; P < .001). Full chimeras receiving (▾, n = 14) or not receiving DLI (▿, n = 7) showed no treatment-related mortality. (B) Mixed chimeras receiving (♦, n = 11) or not receiving (⋄, n = 8) DLI showed no treatment-related mortality. Mixed chimeras receiving DLI and EL4 cells (●, n = 25) had significantly improved survival compared with mixed chimeras receiving EL4 alone (○, n = 14; P < .0001). (C) Mixed chimeras receiving DLI and EL4 cells (●, n = 25) had significantly improved survival compared with full chimeras receiving EL4 + DLI (▪, n = 20; P < .0001).

Close Modal

or Create an Account

Close Modal
Close Modal